Adaptive Biotechnologies Corp. Hits New 52-Week High at $22.54

Adaptive Biotechnologies Corp. has reached a significant milestone by hitting a new 52-week high of USD 22.54 on July 1, 2026. This achievement underscores the company's remarkable performance over the past year, with a staggering increase of 540.97%, significantly outpacing the S&P 500's growth of 20.74% during the same period. As a small-cap player in the Pharmaceuticals & Biotechnology industry, Adaptive Biotechnologies Corp. has a market capitalization of USD 1,911 million. Despite its impressive stock performance, the company is currently loss-making, reflected in its price-to-earnings ratio, which remains unavailable. The firm does not offer a dividend, and its debt-to-equity ratio stands at -0.40, indicating a unique financial structure. Additionally, the return on equity is reported at -27.18%, and the price-to-book ratio is 8.73. The achievement of this new high price highlights Adaptive Biotechnologies Corp.'s position in the market and its significant growth trajectory over the past year.